Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
47 Results for "
Soluble guanylate cyclase
" in MedChemExpress (MCE) Product Catalog:
Products (47)
47 Results for "Soluble guanylate cyclase" in MCE Product Catalog:
19
19 Publications Verification
Synonyms: BAY 632521
Target:
Research Areas:
Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
10
Target:
Research Areas:
Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
4
4 Cited Publications
Synonyms: BAY 58-2667 hydrochloride
Target:
Research Areas:
Cinaciguat hydrochloride is a potent soluble guanylate cyclase (GC) activator with EC50 of 15 nM in platelets.
3
3 Cited Publications
Target:
Research Areas:
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research .
2
Target:
Research Areas:
Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytokines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure .
2
2 Cited Publications
Cat. No.: HY-W013386
CAS No.: 91300-60-6
Target:
Research Areas:
LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .
1
Target:
Research Areas:
Ataciguat (HMR-1766) is a nitric oxide-independent soluble guanylate cyclase (sGC) activator. Ataciguat is able to activate the ferric heme-iron redox form of sGC that stimulate the production of cyclic GMP (cGMP). Ataciguat exhibits vasodilator effects .
1
Target:
Research Areas:
Nelociguat (BAY60-4552) is a nitric oxide sensitive soluble guanylate cyclase stimulator.
1
Target:
Research Areas:
Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .
Synonyms: CY-6463; IW-6463
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Zagociguat (CY-6463) is an orally active and BBB-permeable soluble guanylate cyclase (sGC) stimulator. Zagociguat can increase cGMP levels, regulate blood pressure, improve neuronal function, reduce inflammatory responses, and exert neuroprotective and cognitive-improving effects. Zagociguat can be used in the research of neurodegenerative diseases .
Target:
Research Areas:
(Rac)-MGV354 is the racemate of MGV354. MGV354 is a soluble guanylate cyclase (sGC) activator with EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively .
Cat. No.: HY-137325
CAS No.: 49564-60-5
Target:
Research Areas:
2-Chloro-ATP is a soluble guanylate cyclase inhibitor that increases intracellular calcium concentration at low concentrations through a mechanism independent of inositol phosphate production .
Cat. No.: HY-P11380
CAS No.: 454186-80-2
Research Areas:
Cat. No.: HY-119081
CAS No.: 1160426-89-0
Target:
Research Areas:
GSK2181236A is a NO-insensitive soluble guanylate cyclase (sGC) activator. GSK2181236A can dilate blood vessels, decrease mean arterial pressure and attenuate the development of cardiac hypertrophy. GSK2181236A can be used for the research of cardiovascular disease, such as hypertension .
Cat. No.: HY-137446
CAS No.: 2231749-54-3
Synonyms: BAY 1237592
Target:
Research Areas:
Mosliciguat (BAY 1237592) is an apo-soluble guanylate cyclase activator. Mosliciguat improves cardiopulmonary circulation, reduces pulmonary arterial pressure in animal models, and its efficacy is enhanced under oxidative stress conditions. Mosliciguat exerts a bronchodilatory effect in a rat model of acetylcholine-induced bronchoconstriction. Mosliciguat can be used for research on pulmonary arterial hypertension .
Cat. No.: HY-153369
CAS No.: 1609342-18-8
Synonyms: BAY 1165747
Target:
Research Areas:
BAY-747 (BAY 1165747) is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
Cat. No.: HY-158146
CAS No.: 2101645-33-2
Target:
Research Areas:
sGC activator 1 (example 10B) is an activator of soluble guanylate cyclase (SGC) .
Cat. No.: HY-117962A
CAS No.: 2740807-77-4
Target:
Research Areas:
BI 703704 is a potent soluble guanylate cyclase (sGC) activator. BI 703704 inhibits the progression of diabetic nephropathy in the ZSF1 rat .
Cat. No.: HY-142697
CAS No.: 1426309-31-0
Target:
Research Areas:
SGC agonist 1 is a potent agonist of soluble guanylate cyclase (SGC). SGC agonist 1 improves solubility combined with high cell permeability. SGC agonist 1 has the potential for the research of cardiovascular disease (extracted from patent WO2016030354A1, compound 18A) .
Cat. No.: HY-W007625
CAS No.: 40925-68-6
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
